Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban vs Enoxaparin for VTE Prevention in Spinal Cord Injury
NCT05484557Recruiting
- Sponsor
- Loewenstein Rehabilitation Hospital
- Start
- Sep 2023
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of apixaban in venous thromboembolism (VTE) (2 arms), sponsored by Loewenstein Rehabilitation Hospital. Primary endpoint: Venous Thromboembolism at 2 years. Started Sep 2023; status: recruiting.
02
Drugs
apixaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT05484557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05484557.